Basic information
- CAS
33286-22-5- Standard SMILES
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1.[Cl-].[H+]- InChIKey
HDRXZJPWHTXQRI-BHDTVMLSSA-N- Molecular formula
- C22H27ClN2O4S
- Average molar mass
- 451 g/mol
- Monoisotopic mass
- 450.1380062
Overview
See also: Diltiazem Hydrochloride (preferred); Diltiazem (has active moiety); Diltiazem Malate (related).
Names & identifiers
- Preferred name
- CID 657259
- IUPAC
- [(2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate;hydron;chloride
- English name
- Diltiazem hydrochloride
- Molecular formula
- C22H27ClN2O4S
- Molecular weight
- 450.98
Names & synonyms
SCHEMBL722362DILTIAZEM HCLDILTHIAZEM HYDROCHLORIDETiazacherbesserDiltiazem HydrochloridSprixAcuvailcardizemDilacor XR(2S,cis)-3-(Acetyloxy)-5-[(2-dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one Hydrochloride
Database identifiers
- CAS
33286-22-5- PubChem CID
- 657259
Properties
Computed structural properties
- Topological polar surface area
- 84.4 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 7
- Rotatable bonds
- 7
- Heavy atoms
- 30
- Formal charge
- 0
- Complexity
- 565
Physicochemical properties
- Melting point
- 212 · 212-214 °C
- alpha
- 24 · D24 +98.3 ± 1.4° (c = 1.002 in methanol)
- Density
- 1.3 g/cm3 · 1.30 g/cm3
- refractive index
- 118 ° · 118 ° (C=1, H2O)
- Flash point
- 2 ℃ · 2℃
- storage temp.
- 2 · 2-8°C
- solubility
- Freely soluble in water, in methanol and in methylene chloride, slightly soluble in anhydrous ethanol.
- form
- Powder
- color
- White to off-white
- PH
- pH (10g/l, 25℃) : 4.3～5.3
- Water Solubility
- soluble
- Merck
- 13 · 13,3226
- BRN
- 4228706 · 4228706
- Stability
- 1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20°C for up to 3 months.
- Cosmetics Ingredients Functions
- ASTRINGENTSKIN PROTECTING
- InChI
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- F
- 8-10
- PPE
- dust mask type N95 (US), Eyeshields, Gloves
- wgk
- 3
- rtecs
- DL0310000
- ridadr
- 3249
- hs_code
- 29349990
- Toxicity
- LD50 in male, female mice, male, female rats (mg/kg): 61, 58, 38, 39 i.v.; 260, 280, 520, 550 s.c.; 740, 640, 560, 610 orally (Nagao, 1972)
- risk_code
- 22-40-36/37/38-36-20/21/22-11
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- hazard_code
- Xn,Xi,F
- safety_code
- 36-45-36/37-26-16
- hazard_class
- 6.1(b)
- Storage Class
- 11 - Combustible Solids
- packing_group
- III
- Hazard statements
- H302
- Hazard Classifications
- Acute Tox. 4 Oral
- Precautionary statements
- P301+P312+P330
Chemistry & industry
Applications
DescriptionDiltiazem HCl (33286-22-5) is anon-dihydropyridine-type blocker of L-type Ca2+ channels.1,2 Reduces Ca2+ oscillations in subcellular compartments in vascular smooth muscle cells.3Also blocks P-type Ca2+ channels in freshly dissociated rat cerebellar Purkinje neurons.4 Clinically useful antihypertensive agent.5Cell permeable.
UsesDiltiazem Hydrochloride is a calcium channel blocker with vasodilating activity. Anti-anginal; anti-hypertensive; anti-arrhythmic (class IV).
Usesantihypertensive, sedative, antibacterial
UsesPeripheral Vasodilator
UsesAn antianginal, antihypertensive. Regulates Calcium release from intracellular stores in neutrophils
General DescriptionDiltiazem hydrochloride is a calcium ion cellular influx inhibitor. It was developed and introduced inJapan as a cardiovascular agent to treat angina pectoris. Itwas observed to dilate peripheral arteries and arterioles. Thedrug increases myocardial oxygen supply by relieving coronaryartery spasm and reduces myocardial oxygen demandby decreasing heart rate and reducing overload. Diltiazemhydrochloride is used in patients with variant angina. Thedrug has electrophysiological properties similar to those ofverapamil and is used in clinically similar treatment conditionsas an antiarrhythmic agent, but it is less potent.The drug is absorbed rapidly and almost completely fromthe digestive tract. It reaches peak plasma levels within 1hour after administration in gelatin capsules. Oral formulationson the market are sustained-release preparations providingpeak plasma levels 3 to 4 hours after administration.
Upstream & downstream products
Upstream raw materials
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…